EurekaMag.com logo
+ Site Statistics
References:
52,725,316
Abstracts:
28,411,598
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals






Plos One 10(1): E0117904-E0117904

The major birch pollen allergen Bet v 1 induces different responses in dendritic cells of birch pollen allergic and healthy individuals

Dendritic cells play a fundamental role in shaping the immune response to allergens. The events that lead to allergic sensitization or tolerance induction during the interaction of the major birch pollen allergen Bet v 1 and dendritic cells are not very well studied. Here, we analyzed the uptake of Bet v 1 and the cross-reactive celery allergen Api g 1 by immature monocyte-derived dendritic cells (iMoDCs) of allergic and normal donors. In addition, we characterized the allergen-triggered intracellular signaling and transcriptional events. Uptake kinetics, competitive binding, and internalization pathways of labeled allergens by iMoDCs were visualized by live-cell imaging. Surface-bound IgE was detected by immunofluorescence microscopy and flow cytometry. Allergen- and IgE-induced gene expression of early growth response genes and Th1 and Th2 related cytokines and chemokines were analyzed by real-time PCR. Phosporylation of signaling kinases was analyzed by Western blot. Internalization of Bet v 1 by iMoDCs of both donor groups, likely by receptor-mediated caveolar endocytosis, followed similar kinetics. Bet v 1 outcompeted Api g 1 in cell surface binding and uptake. MoDCs of allergic and healthy donors displayed surface-bound IgE and showed a pronounced upregulation of Th2 cytokine- and NFκB-dependent genes upon non-specific Fcε receptor cross-linking. In contrast to these IgE-mediated responses, Bet v 1-stimulation increased transcript levels of the Th2 cytokines IL-4 and IL-13 but not of NFκB-related genes in MoDCs of BP allergic donors. Cells of healthy donors were either unresponsive or showed elevated mRNA levels of Th1-promoting chemokines. Moreover, Bet v 1 was able to induce Erk1/2 and p38 MAPK activation in BP allergics but only a slight p38 activation in normal donors. In conclusion, our data indicate that Bet v 1 favors the activation of a Th2 program only in DCs of BP allergic individuals.


Accession: 059084753

PMID: 25635684

DOI: 10.1371/journal.pone.0117904



Related references

Gafvelin, G.; Thunberg, S.; Kronqvist, M.; Grönlund, H.; Grönneberg, R.; Troye-Blomberg, M.; Akdis, Mübeccel.; Fiebig, H.; Purohit, A.; Horak, F.; Reisinger, Jürgen.; Niederberger, V.; Akdis, C.A.; Cromwell, O.; Pauli, G.; Valenta, R.; van Hage, M., 2005: Cytokine and antibody responses in birch-pollen-allergic patients treated with genetically modified derivatives of the major birch pollen allergen Bet v 1. Background: Recently, recombinant hypoallergenic derivatives of the major birch pollen allergen, Bet v 1, were used to treat birch-pollen-allergic patients in a double-blind, placebo-controlled, multi-centre immunotherapy study. The aim of this st...

Larenas-Linnemann, Désirée., 2010: Oralair Birch, a recombinant major birch pollen allergen tablet for sublingual immunotherapy of allergic rhinitis caused by birch pollen. Oralair Birch is a dissolving tablet being developed for sublingual immunotherapy (SLIT) of allergic rhinitis caused by birch pollen allergy. Oralair Birch is being developed by Stallergenes SA and Canadian licensee Paladin Labs Inc. Oralair Birch...

Nopp, A.; Halldén, G.; Lundahl, J.; Johansson, E.; Vrtala, S.; Valenta, R.; Grönneberg, R.; Van Hage-Hamsten, M., 2000: Comparison of inflammatory responses to genetically engineered hypoallergenic derivatives of the major birch pollen allergen bet v 1 and to recombinant bet v 1 wild type in skin chamber fluids collected from birch pollen-allergic patients. Background: Nearly 60% of birch pollen-allergic patients react exclusively to Bet v 1. With use of the skin blister model, previously only established for installation of crude allergens, we have for the first time characterized the inflammatory r...

Grote, M.; Wiedemann, P.; Lebecque, S.; Valenta, R., 1998: Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of the major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Human monoclonal antibodies (BAB1, BAB2 and BAB4), derived from an individual allergic to pollen of white birch (Betula verrucosa) [B. pendula], were incubated with ultrathin sections of birch pollen grains and binding sites were determined by sca...

Grote, M.; Wiedemann, P.; Lebecque, S.; Valenta, R., 1998: Human monoclonal IgG antibodies derived from a patient allergic to birch pollen as tools to study the in situ localization of major birch pollen allergen, Bet v 1, by immunogold electron microscopy. Background: Bet v 1, the major birch pollen allergen, and related allergens present in various tree pollens, fruits, and vegetables represent a family of important cross-reactive allergens. Although the DNA, deduced amino-acid sequence, and struct...

Van Hage Hamsten, M.; Johansson, E.; Roquet, A.; Peterson, C.; Andersson, M.; Vrtala, S.; Valenta, R.; Gronneberg, R., 2001: Recombinant derivatives of the major birch pollen allergen Bet v 1, which induce fewer symptoms and lower mediator release and eosinophil activation than rBet v 1 wild-type in nasal challenges in birch pollen allergic patients. Allergy (Copenhagen) 56(Supplement 68): 94

Smole, U.; Wagner, S.; Balazs, N.; Radauer, C.; Bublin, M.; Allmaier, G.; Hoffmann-Sommergruber, K.; Breiteneder, H., 2011: Bet v 1 and its homologous food allergen Api g 1 stimulate dendritic cells from birch pollen-allergic individuals to induce different Th-cell polarization. Bet v 1 is the most relevant sensitizing protein for birch pollen (BP)-allergic individuals. Its homologues from plant foods are mainly involved in allergic reactions caused by IgE cross reactivity. We aimed to evaluate the polarizing effect of de...

Godnic-Cvar, J.; Susani, M.; Breiteneder, H.; Berger, A.; Havelec, L.; Waldhör, T.; Hirschwehr, R.; Valenta, R.; Scheiner, O.; Rüdiger, H.; Kraft, D.; Ebner, C., 1997: Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in vitro and in...

Godnic Cvar, J.; Susani, M.; Breiteneder, H.; Berger, A.; Havelec, L.; Waldhor, T.; Hirschwehr, R.; Valenta, R.; Scheiner, O.; Rudiger, H.; Kraft, D.; Ebner, C., 1997: Recombinant Bet v 1, the major birch pollen allergen, induces hypersensitivity reactions equal to those induced by natural Bet v 1 in the airways of patients allergic to tree pollen. Background: Atopic allergens produced by recombinant DNA methods are promising tools for diagnosis and therapy of Type I allergy. To evaluate the immunologic properties of these molecules, it is necessary to compare them with natural allergens in...

Mahler, V.; Vrtala, S.; Kuss, O.; Diepgen, T.L.; Cromwell, O.; Fiebig, H.; Schuler, G.; Kraft, D.; Valenta, R., 2001: Vaccines for birch pollen allergy based on genetically-engineered hypoallergenic derivatives of the major birch pollen allergen, Bet v 1. Allergy (Copenhagen) 56(Supplement 68): 60